Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTICAL: MSCTRAIL in Lung Cancer
NCT03298763Phase 2Unknown
- Sponsor
- University College London
- Start
- Mar 2019
- Primary completion
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSCTRAIL in lung adenocarcinoma (3 arms), sponsored by University College London. Primary endpoints: Recommended Phase II Dose and Tumour Response Rate at 12 weeks. Status: unknown.
02
Drugs
MSCTRAIL
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03298763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298763.